83 related articles for article (PubMed ID: 23592596)
1. A machine-assisted flow synthesis of SR48692: a probe for the investigation of neurotensin receptor-1.
Battilocchio C; Deadman BJ; Nikbin N; Kitching MO; Baxendale IR; Ley SV
Chemistry; 2013 Jun; 19(24):7917-30. PubMed ID: 23592596
[TBL] [Abstract][Full Text] [Related]
2. The non-peptide neurotensin receptor antagonist SR48692 is not a potent antagonist of neurotensin(8-13) responses of rat substantia nigra neurones in vitro.
Pinnock RD; Woodruff GN
Neurosci Lett; 1994 May; 172(1-2):175-8. PubMed ID: 8084529
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692.
Iwase K; Evers BM; Hellmich MR; Kim HJ; Higashide S; Gully D; Thompson JC; Townsend CM
Cancer; 1997 May; 79(9):1787-93. PubMed ID: 9128997
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with SR48692 has different effects on central neurotensin-induced gastric mucosal defense and inhibition of gastric acid secretion in rats.
Karinch AM; Schmidt GL; Kauffman GL
Brain Res; 1998 Nov; 810(1-2):123-9. PubMed ID: 9813278
[TBL] [Abstract][Full Text] [Related]
5. In Silico Investigation of the Neurotensin Receptor 1 Binding Site: Overlapping Binding Modes for Small Molecule Antagonists and the Endogenous Peptide Agonist.
Lückmann M; Holst B; Schwartz TW; Frimurer TM
Mol Inform; 2016 Jan; 35(1):19-24. PubMed ID: 27491650
[TBL] [Abstract][Full Text] [Related]
6. X-ray structural characterization of SR 142948, a novel potent synthetic neurotensin receptor antagonist.
Quéré L; Longfils G; Boigegrain R; Labeeuw B; Gully D; Durant F
Bioorg Med Chem Lett; 1998 Mar; 8(6):653-8. PubMed ID: 9871577
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells.
Oury-Donat F; Thurneyssen O; Gonalons N; Forgez P; Gully D; Le Fur G; Soubrie P
Br J Pharmacol; 1995 Sep; 116(2):1899-905. PubMed ID: 8528577
[TBL] [Abstract][Full Text] [Related]
8. The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.
Thomas JB; Navarro H; Warner KR; Gilmour B
Bioorg Med Chem Lett; 2009 Mar; 19(5):1438-41. PubMed ID: 19195889
[TBL] [Abstract][Full Text] [Related]
9. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
Zhang Y; Zhu S; Yi L; Liu Y; Cui H
Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116
[TBL] [Abstract][Full Text] [Related]
10. Central administration of the neurotensin receptor antagonist, SR48692, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity.
Rowe WB; Nicot A; Sharma S; Gully D; Walker CD; Rostène WH; Meaney MJ; Quirion R
Neuroendocrinology; 1997 Aug; 66(2):75-85. PubMed ID: 9263204
[TBL] [Abstract][Full Text] [Related]
11. The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice.
Costa FG; Frussa-Filho R; Felicio LF
Eur J Pharmacol; 2001 Sep; 428(1):97-103. PubMed ID: 11779043
[TBL] [Abstract][Full Text] [Related]
12. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth.
Iwase K; Evers BM; Hellmich MR; Kim HJ; Higashide S; Gully D; Townsend CM
Surg Oncol; 1996; 5(5-6):245-51. PubMed ID: 9129137
[TBL] [Abstract][Full Text] [Related]
13. SR142948A is a potent antagonist of the cardiovascular effects of neurotensin.
Schaeffer P; Laplace MC; Bernat A; Prabonnaud V; Gully D; Lespy L; Herbert JM
J Cardiovasc Pharmacol; 1998 Apr; 31(4):545-50. PubMed ID: 9554803
[TBL] [Abstract][Full Text] [Related]
14. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells.
Moody TW; Chiles J; Casibang M; Moody E; Chan D; Davis TP
Peptides; 2001 Jan; 22(1):109-15. PubMed ID: 11179604
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
Baxendale IR; Cheung S; Kitching MO; Ley SV; Shearman JW
Bioorg Med Chem; 2013 Jul; 21(14):4378-87. PubMed ID: 23721919
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation.
Valerie NC; Casarez EV; Dasilva JO; Dunlap-Brown ME; Parsons SJ; Amorino GP; Dziegielewski J
Cancer Res; 2011 Nov; 71(21):6817-26. PubMed ID: 21903767
[TBL] [Abstract][Full Text] [Related]
17. [Neurotensin receptor antagonists and therapeutical perspectives].
Gully D; Maffrand JP; Soubrié P; Rostène W; Kitabgi P; Le Fur G
Therapie; 1995; 50(1):5-7. PubMed ID: 7754478
[TBL] [Abstract][Full Text] [Related]
18. The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats.
Chapman MA; See RE
Brain Res; 1996 Aug; 729(1):124-6. PubMed ID: 8874884
[TBL] [Abstract][Full Text] [Related]
19. Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons in primary culture.
Antonelli T; Tomasini MC; Finetti S; Giardino L; Calzà L; Fuxe K; Soubriè P; Tanganelli S; Ferraro L
J Neurosci Res; 2002 Dec; 70(6):766-73. PubMed ID: 12444598
[TBL] [Abstract][Full Text] [Related]
20. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692.
Herzig MC; Chapman WG; Sheridan A; Rake JB; Woynarowski JM
Anticancer Res; 1999; 19(1A):213-9. PubMed ID: 10226545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
